Highlighting the Benefits of Therapeutic Gardens in Alzheimer's Disease by 18F-FDG Cerebral PET /CT

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Aug 12, 2020

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with AD in the mild to moderate stage, followed at the memory and resource center (CMRR) (MMS 15-23) and having had a 18F-FDG PET-CT (Positon emission tomography) scan in routine care having a companion for the duration of the study .
• • Patient with a neuropsychological assessment (MOCA, DO80, BREF, HAD) of less than 3 months. (If the last neuropsychological assessment dates from more than 3 months, these tests are carried out in routine care during the consultation was proposed and the consent obtained)
• • Symptomatic treatment of AD (anticholinesterase or memantine) if prescribed, at a stable dose for 1 month, stable psychotropic treatment for 1 month
• • Person affiliated with a social security scheme or beneficiary of such a scheme.
• • Patient over 18 years old.
• • Person received complete information on the organization of the research and having signed their informed consent.
• Exclusion Criteria:
• • Patient who did not have biomarkers identified by lumbar puncture
• • Patient unable to perform a cerebral 18F-FDG PET-CT scan (lying position for more than 20 minutes)
• • Patient unable to follow the therapeutic program of the garden.
• • Woman of childbearing age whitout effective contraception.
• • Pregnant woman or nursing mother.
• • Person referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the public health code.
• • Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric treatment under articles L. 3212-1 and L. 3213-1